Abstract
Background CHADS2 and CHA2DS2-VASc scores are widely used for thromboembolic risk assessment in Atrial Fibrillation(AF) cohort, however further utilization to predict outcomes is understudied. Method HCUP's National Readmission Data(NRD) 2013 was queried for AF admissions using ICD-9-CM code 427.31 in principal diagnosis field. Patients with mitral valve disease or repair/or replacement were excluded to estimate population with non-valvular AF only. CHADS2 and CHA2DS2-VASc were calculated for each patient. Hierarchical two-level logistic and linear models were used to evaluate study outcomes in terms of mortality, 30 or 90-day readmissions, length of stay(LOS) and cost. Result Of 116,450 principal non-valvular AF admissions(50.2% female and 43.1% age ≥ 75 years) 29,179 patients were readmitted, with total 40,959 readmissions. Higher CHADS2 and CHA2DS2-VASc score were associated with increased mortality from 0.4% for CHADS2 of 0 to 3.2% for score of 6 and from 0.2% for CHA2DS2-VASc of 0 to 3.2% for score ≥ 8. LOS increased from 2.20 days for CHADS2 of 0 to 5.08 days for score of 6, while cost increased from $7888 to $11,151. 30-day readmission rate increased from 8.9% for CHADS2 of 0 to 26.0% for score of 6, and 90-day readmission rate increased from 15.2% to 39%. CHA2DS2-VASc scoring similarly demonstrated a trend towards increasing readmission rate, LOS and cost for higher scores. Also, similar results were seen in hierarchical modeling with increment of CHADS2 and CHA2DS2-VASc scores. Conclusion CHADS2 and CHA2DS2-VASc scores can be used as quick surrogate markers for predicting outcomes beyond thromboembolic risk. Physician familiarity with these systems makes them easy to use bedside clinical tools to improve outcomes and resource allocation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 162-167 |
| Number of pages | 6 |
| Journal | International Journal of Cardiology |
| Volume | 245 |
| DOIs | |
| State | Published - Oct 15 2017 |
Fingerprint
Keywords
- Atrial fibrillation
- CHADS-VASc
- CHADS
- Mortality
- Readmission
ASJC Scopus subject areas
- Medicine(all)
- Cardiology and Cardiovascular Medicine
Cite this
Atrial fibrillation : Utility of CHADS2 and CHA2DS2-VASc scores as predictors of readmission, mortality and resource utilization. / Lahewala, Sopan; Arora, Shilpkumar; Patel, Prashant; Kumar, Varun; Patel, Nirali; Tripathi, Byomesh; Patel, Nilay; Kallur, Kamala Ramya; Shah, Harshil; Syed, Amer; Gidwani, Umesh; Viles Gonzalez, Juan; Deshmukh, Abhishek.
In: International Journal of Cardiology, Vol. 245, 15.10.2017, p. 162-167.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Atrial fibrillation
T2 - Utility of CHADS2 and CHA2DS2-VASc scores as predictors of readmission, mortality and resource utilization
AU - Lahewala, Sopan
AU - Arora, Shilpkumar
AU - Patel, Prashant
AU - Kumar, Varun
AU - Patel, Nirali
AU - Tripathi, Byomesh
AU - Patel, Nilay
AU - Kallur, Kamala Ramya
AU - Shah, Harshil
AU - Syed, Amer
AU - Gidwani, Umesh
AU - Viles Gonzalez, Juan
AU - Deshmukh, Abhishek
PY - 2017/10/15
Y1 - 2017/10/15
N2 - Background CHADS2 and CHA2DS2-VASc scores are widely used for thromboembolic risk assessment in Atrial Fibrillation(AF) cohort, however further utilization to predict outcomes is understudied. Method HCUP's National Readmission Data(NRD) 2013 was queried for AF admissions using ICD-9-CM code 427.31 in principal diagnosis field. Patients with mitral valve disease or repair/or replacement were excluded to estimate population with non-valvular AF only. CHADS2 and CHA2DS2-VASc were calculated for each patient. Hierarchical two-level logistic and linear models were used to evaluate study outcomes in terms of mortality, 30 or 90-day readmissions, length of stay(LOS) and cost. Result Of 116,450 principal non-valvular AF admissions(50.2% female and 43.1% age ≥ 75 years) 29,179 patients were readmitted, with total 40,959 readmissions. Higher CHADS2 and CHA2DS2-VASc score were associated with increased mortality from 0.4% for CHADS2 of 0 to 3.2% for score of 6 and from 0.2% for CHA2DS2-VASc of 0 to 3.2% for score ≥ 8. LOS increased from 2.20 days for CHADS2 of 0 to 5.08 days for score of 6, while cost increased from $7888 to $11,151. 30-day readmission rate increased from 8.9% for CHADS2 of 0 to 26.0% for score of 6, and 90-day readmission rate increased from 15.2% to 39%. CHA2DS2-VASc scoring similarly demonstrated a trend towards increasing readmission rate, LOS and cost for higher scores. Also, similar results were seen in hierarchical modeling with increment of CHADS2 and CHA2DS2-VASc scores. Conclusion CHADS2 and CHA2DS2-VASc scores can be used as quick surrogate markers for predicting outcomes beyond thromboembolic risk. Physician familiarity with these systems makes them easy to use bedside clinical tools to improve outcomes and resource allocation.
AB - Background CHADS2 and CHA2DS2-VASc scores are widely used for thromboembolic risk assessment in Atrial Fibrillation(AF) cohort, however further utilization to predict outcomes is understudied. Method HCUP's National Readmission Data(NRD) 2013 was queried for AF admissions using ICD-9-CM code 427.31 in principal diagnosis field. Patients with mitral valve disease or repair/or replacement were excluded to estimate population with non-valvular AF only. CHADS2 and CHA2DS2-VASc were calculated for each patient. Hierarchical two-level logistic and linear models were used to evaluate study outcomes in terms of mortality, 30 or 90-day readmissions, length of stay(LOS) and cost. Result Of 116,450 principal non-valvular AF admissions(50.2% female and 43.1% age ≥ 75 years) 29,179 patients were readmitted, with total 40,959 readmissions. Higher CHADS2 and CHA2DS2-VASc score were associated with increased mortality from 0.4% for CHADS2 of 0 to 3.2% for score of 6 and from 0.2% for CHA2DS2-VASc of 0 to 3.2% for score ≥ 8. LOS increased from 2.20 days for CHADS2 of 0 to 5.08 days for score of 6, while cost increased from $7888 to $11,151. 30-day readmission rate increased from 8.9% for CHADS2 of 0 to 26.0% for score of 6, and 90-day readmission rate increased from 15.2% to 39%. CHA2DS2-VASc scoring similarly demonstrated a trend towards increasing readmission rate, LOS and cost for higher scores. Also, similar results were seen in hierarchical modeling with increment of CHADS2 and CHA2DS2-VASc scores. Conclusion CHADS2 and CHA2DS2-VASc scores can be used as quick surrogate markers for predicting outcomes beyond thromboembolic risk. Physician familiarity with these systems makes them easy to use bedside clinical tools to improve outcomes and resource allocation.
KW - Atrial fibrillation
KW - CHADS-VASc
KW - CHADS
KW - Mortality
KW - Readmission
UR - http://www.scopus.com/inward/record.url?scp=85028577464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028577464&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2017.06.090
DO - 10.1016/j.ijcard.2017.06.090
M3 - Article
C2 - 28874288
AN - SCOPUS:85028577464
VL - 245
SP - 162
EP - 167
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
ER -